| Phase 1 safety trials for begin for deuterium-based drug targeting diabetic kidney disease. |
|
| Mass High Tech: The trial will recruit healthy volunteers to be given a single ascending dose of CTP-499 to test the tolerability and safety of the drug. Later this year the company expects to start a Phase 2a efficacy trial using the drug and placebo with a current standard-of-care drug such as an angiotensin inhibitor that helps lower blood pressure to protect kidney function. |